This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - FrançiasSearch

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page
AboutAbout  CRESEMBA®Invasive fungal infections and risk factorsMeet CRESEMBA ®CRESEMBA® patient profilesVirtual Patient ExperienceEfficacyEfficacyInvasive AspergillosisMucormycosis

Menu

Close

LabelDosingDosingDosingSafety ProfileSafety & TolerabilitySafety ProfileEmerging PopulationsEmerging PopulationsICUInvasive fungal infections in the ICUInvasive fungal infections and influenza

Invasive fungal infections in solid organ transplant recipients

Invasive fungal infections and chronic obstructive pulmonary disease

Invasive fungal infections and COVID-19 (CAPA/CAM)Support & ResourcesResourcesKOL VideosNational/Regional GuidelinesECIL-6 Guidelines
ESCMID
ID Society of AmericaVideos
MaterialsSupport & Resources

Information on how to access prescribing information and adverse event reporting can be found towards the bottom of the page.

Invasive fungal infections are a growing problem1–4

Despite progress in diagnostics and treatment, invasive fungal infections continue to pose a significant threat.1–4

Among these, invasive mould infections like invasive aspergillosis and mucormycosis are of particular concern due to their high mortality rates.1,5

What is an invasive mould infection?

Learn more about invasive mould disease, who’s at risk and emerging risk factors

The incidence of invasive mould infections has increased in recent years.1,2

Estimated annual global cases of leading mould infections6

 Estimated annual global cases of leading mould infections6

50% of invasive mould infections are diagnosed before death,7 and discriminating between invasive aspergillosis and mucormycosis in a timely fashion can prove difficult.8

This has detrimental consequences, as delayed diagnosis and treatment are associated with very high mortality.8

Mortality rates in invasive aspergillosis and mucormycosis

Mortality with invasive fungal infections can vary depending on the underlying condition5

Mortality rates in invasive aspergillosis and mucormycosis

Mortality with invasive fungal infections can vary depending on the underlying condition5

Invasive fungal infections in immunocompromised patients

Invasive fungal infections commonly affect people with a compromised or weakened immune system.13

Host risk factors13

 Host risk factors13

Despite the availability of treatment options and advances in diagnostic techniques, the management of invasive fungal infections remains complex. In addition, incidence has substantially increased, due to growing numbers of patients with risk factors such as:1–3,14

  • Potent immunosuppressive regimens
  • Certain chemotherapy agents
  • A rise in the number of transplants
  • Aggressive transplant protocols
 Can MYLOTARG  help your patients with haematologic malignancies?

MYLOTARG is indicated for combination therapy with daunorubicin (DNR) and cytarabine (AraC) for the treatment of patients aged 15 years and above with previously untreated, de novo CD33-positive acute myeloid leukaemia (AML), except acute promyelocytic leukaemia (APL)33

Learn more about MYLOTARGLoadingAspergillus and Mucorales are the most common pathogens causing invasive mould infections in immunocompromised cancer and HSCT patients3

Aspergillus and Mucorales in HSCT and haematological malignancy

 Aspergillus and Mucorales in HSCT and haematological malignancy In HSCT recipients, the incidence of invasive fungal infections varies with the type of transplant18Incidence by type of HSCT

Based on 12-month cumulative incidence calculated for 15,820 incidence cohort patients.

Patients receiving a solid organ transplant are also at risk of developing invasive aspergillosis6,19,20

Incidence of aspergillosis by type of solid organ transplant

 Incidence of aspergillosis by type of solid organ transplant

The incidence rates of mucormycosis range from 0.4% to 16.0% depending on the procedure and geographical area.21

Emerging at-risk populations

In addition to traditionally at-risk immunocompromised patients, invasive aspergillosis is increasingly observed in other categories of non-neutropenic patients, such as those with COPD or treated with certain treatments. Patients admitted to the ICU are also emerging as a population susceptible to developing invasive aspergillosis.22–24

Emerging populations for invasive aspergillosis

 Emerging populations for invasive aspergillosis Explore more
Learn more about the need for alternative antifungal agents
 Discover the value of CRESEMBA® Loading

a. Invasive aspergillosis risk ranged from 4% (during remission-induction, with prophylaxis) to 11% (during remission-induction, without prophylaxis).16

AML, acute myeloid leukaemia; COPD, chronic obstructive pulmonary disease; HSCT, haematopoietic stem cell transplantation; ICU, intensive care unit; STAT 3, signal transducer and activator of transcription 3.

Prescribing Information:

Click here for CRESEMBA® (isavuconazole) prescribing information
Click here for MYLOTARG®(gemtuzumab ozogamicin) & cytarabine prescribing information

References:

Binder U and Lass-Florl C. Mediterr J Hematol Infect Dis 2011;3(1):e20110016.Low CY and Rotstein C. F1000 Med Rep 2011;3:14.Natesan SK and Chandrasekar PH. Infect Drug Resist 2016;9:291–300.Perfect JR. Nat Rev Drug Discov 2017;16(9):603–616.Lin SJ et al. Clin Infect Dis 2001;32(3):358–366.Bongomin F et al. J Fungi (Basel) 2017;3(4).Dignani MC. F1000Prime Rep 2014;6:81.Chamilos G et al. Clin Infect Dis 2008;47(4):503–509.Garcia-Vidal C et al. PLoS One 2015;10(3):e0120370.Guinea J et al. PLoS One 2017;12(6):e0179136.Roden MM et al. Clin Infect Dis 2005;41(5):634–653.Skiada A et al. Clin Microbiol Infect 2011;17(12):1859–1867.Donnelley JP et al. Clin Infect Dis 2020;71(6);1367–1376.Mercier T and Maertens J. J Antimicrob Chemother 2017;72(suppl_1):i29–i38.Lass-Florl C and Cuenca-Estrella M. J Antimicrob Chemother 2017;72(suppl_1):i5–i11.van de Peppel RJ et al. J Infect 2018;76:550–562.Lanternier F et al. Clin Infect Dis 2012;54(11):1–8.Kontoyiannis DP et al. Clin Infect Dis 2010;50(8):1091–1100.Husain S and Camargo JF. Clin Transplant 2019;33:e13544.Aguilar C et al. F1000Res 2018;7:661.Garcia-Vidal C et al. J Antimicrob Chemother 2019;74(Suppl 2):ii16–ii20.Bassetti M et al. Infect Dis Ther 2018;7(1):17–27.Taccone FS et al. Crit Care 2015;19:7.ECDC. Influenza-associated invasive pulmonary aspergillosis, Europe. 2018. Available from:
https://www.ecdc.europa.eu/sites/portal/files/documents/aspergillus-and-influenza-rapid-risk-assessment-november-2018.pdf Accessed February 2023.Bassetti M et al. IDCases 2018;12:7–9.Schauwvlieghe A et al. Lancet Respir Med 2018;6(10):782–792.Wauters J et al. Intensive Care Med 2012;38(11):1761–1768.Feys S et al. J Fungi (Basel) 2021;7(12):1067.Chamilos G et al. Clin Infect Dis 2018;66(1):140–148.Cummins KC et al. Leuk Lymphoma 2019;60(2):527–530.Ghez D et al. Blood 2018;131(17):1955–1959.Chang CC and Levitz SM. Med Mycol 2019;57(Supplement_3):S294–S306.MYLOTARG Summary of Product Characteristics for Great Britain. MYLOTARG Summary of Product Characteristics for Northern Ireland
PP-CRB-GBR-1978. July 2023
About How can CRESEMBA® help your invasive aspergillosis patients? Explore the clinical data Loading Learn about invasive fungal infections in the ICU Discover the impact Loading

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2024 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7866. January 2024
You are now leaving PfizerPro​​​​​
​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024

YesNo
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​